Kissei Pharmaceutical's Partner JW Pharmaceutical Gains Approval for Tavalisse in South Korea
The 18% Return This Week Takes Rigel Pharmaceuticals' (NASDAQ:RIGL) Shareholders One-year Gains to 56%
Rigel Pharmaceuticals To Present At J.P. Morgan Healthcare Conference; Webcast At 11:15 AM ET
Rigel Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57
Rigel Reports Q4 2024 Revenue Of $57.6M With TAVALISSE $31M, REZLIDHIA $7.4M, GAVRETO $8.1M; R289 Receives FDA Orphan Drug Status For MDS; 2025 Revenue Projected At $200M-$210M
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Salem Moooon : How or when do you decide to take your profits?
Jenna Ragan OP Salem Moooon : I'll take small amounts at 20%+
but I'm fully involved in most of these, I know what I'm hanging on to, so I'm waiting for more news and lots higher prices to sell all
Joseph Busciglio : This is after you just lost your ass on all of these I am sure. LOL Those ReBuy Prices Sold you out!
Jenna Ragan OP Joseph Busciglio : I have no clue of what you are talking about.
hope you had a profitable day
Boxman Jenna Ragan OP :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
View more comments...